Drug Type Small molecule drug |
Synonyms DNX-114 |
Target |
Action inhibitors |
Mechanism TNF inhibitors(Tumor necrosis factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Preclinical | United States | 31 Aug 2022 | |
Arthritis, Psoriatic | Preclinical | United States | 31 Aug 2022 | |
Juvenile Idiopathic Arthritis | Preclinical | United States | 31 Aug 2022 | |
Plaque psoriasis | Preclinical | United States | 31 Aug 2022 | |
Rheumatoid Arthritis | Preclinical | United States | 31 Aug 2022 |